Cargando…
Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations
The development of thrombotic events is common among patients with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). We studied the influence of pathogenic mutations frequently associated with myeloid malignancies on thrombotic events using next-generation sequ...
Autores principales: | Segura-Díaz, Adrián, Stuckey, Ruth, Florido, Yanira, González-Martín, Jesús María, López-Rodríguez, Juan Francisco, Sánchez-Sosa, Santiago, González-Pérez, Elena, Perdomo, María Nieves Sáez, Perera, María del Mar, de la Iglesia, Silvia, Molero-Labarta, Teresa, Gómez-Casares, María Teresa, Bilbao-Sieyro, Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226609/ https://www.ncbi.nlm.nih.gov/pubmed/32290079 http://dx.doi.org/10.3390/cancers12040934 |
Ejemplares similares
-
P1001: DNMT3A/TET2/ASXL1 MUTATIONS DETERMINE THROMBOTIC RISK IN POLYCYTHAEMIA VERA
por: Segura Diaz, A., et al.
Publicado: (2022) -
CALR mutation characterization in myeloproliferative neoplasms
por: Bilbao-Sieyro, Cristina, et al.
Publicado: (2016) -
BCL2 Expression at Post-Induction and Complete Remission Impact Outcome in Acute Myeloid Leukemia
por: Bilbao-Sieyro, Cristina, et al.
Publicado: (2020) -
Can the Gene Expression Profile of Patients with Acute Myeloid Leukemia Predict Complete Remission Following Induction Therapy?
por: Sánchez-Sosa, Santiago, et al.
Publicado: (2022) -
Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment
por: Stuckey, Ruth, et al.
Publicado: (2023)